Table 3.

Risk of colorectal cancer in users of antidiabetic drugs, stratified by gender

MenWomen
Drugs and no. prescriptionsCases/ControlsAdjusted ORa (95% CI)Cases/ControlsAdjusted ORa (95% CI)
Metformin
 No prior use312/2,0391.00 (ref)192/1,1261.00 (ref)
 1–973/4201.18 (0.88–1.58)38/2450.85 (0.57–1.27)
 10–2984/4791.23 (0.93–1.64)42/2840.82 (0.55–1.21)
 30–4951/2771.29 (0.90–1.84)28/1530.98 (0.61–1.57)
 ≥5062/2771.81 (1.25–2.62)38/2201.00 (0.63–1.58)
Sulfonylureas
No prior use291/1,7461.00 (ref)171/1,0371.00 (ref)
 1–961/3351.04 (0.76–1.41)33/2051.01 (0.67–1.53)
 10–2995/5820.89 (0.67–1.16)48/3020.98 (0.67–1.42)
 30–4965/3510.97 (0.70–1.35)39/2081.19 (0.78–1.81)
 ≥5070/4780.65 (0.46–0.92)47/2761.05 (0.68–1.61)
Insulin
No prior use498/2,9271.00 (ref)278/16571.00 (ref)
 1–919/1001.15 (0.69–1.91)13/731.08 (0.58–2.00)
 10–2921/1700.71 (0.44–1.14)10/1070.55 (0.28–1.08)
 30–4921/1171.10 (0.67–1.81)15/811.11 (0.61–2.02)
 ≥5023/1780.72 (0.44–1.17)22/1101.17 (0.69–2.00)
  • aAdjusted for each other, diabetes duration, BMI, smoking, prior use of aspirin, NSAID, and statins (women: additionally adjusted for estrogen use).